EGFR and non-small cell lung carcinoma: Patients with KRAS mutations represent approximately 25% of NSCLC patients and have been described as highly resistant to EGFR-TKI treatment with RR close to 0% and worse outcome for mutated patients treated with EGFR-TKIs in some trials [36], [37].